Protection of mice and nude rats against toxoplasmosis by a multiple antigenic peptide construction derived from Toxoplasma gondii P30 antigen
- PMID: 1431132
Protection of mice and nude rats against toxoplasmosis by a multiple antigenic peptide construction derived from Toxoplasma gondii P30 antigen
Abstract
The first part of this work presents the sequence of the first 20 NH2 terminus residues obtained from P30, the major surface Ag of Toxoplasma gondii, purified by HPLC. A synthetic peptide (P30 48-67) has been prepared both in linear form and as a multiple antigenic peptide (MAP) construct. Immunization of mice and rats with the P30 48-67 MAP in the presence of IFA induces high levels of IgG antibodies that recognize both the linear peptide and the MAP construct in ELISA, and P30 in Western blots of NP-40-extracted tachyzoite Ag. Because these sera are negative in immunofluorescence assays with whole tachyzoites, it seems that IgG antibodies induced by P30 48-67 MAP, although recognizing the denatured structure, are unable to recognize the native protein. However, the protective effect of both constructs has then been studied in mice and nude rats. Whereas immunization of mice with the monomeric peptide does not confer any protection against oral infection with 1200 cysts of T. gondii 76K strain (mortality within 11 days), 40% of mice immunized with the MAP construct survived up to 75 days after infection. Nude rats were passively transferred with 5 x 10(4) T lymphocytes from P30 48-67 MAP-immunized Fischer rats before infection with 5 x 10(4) RH strain tachyzoites. They survived up to 40 days after infection and raised an intense IgG antibody response against P30, whereas nude rats transferred with control lymphocytes died within 21 days. This shows that immunization with P30 48-67 MAP also induces an efficient T cell immune response. The present work confirms the recently demonstrated role of P30 in protective immunity and shows the interest of peptide octameric constructions as inducers of partially protective immune responses in toxoplasmosis, as already demonstrated in schistosomiasis.
Similar articles
-
Antibodies to Toxoplasma gondii major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection.J Immunol. 1993 May 1;150(9):3951-64. J Immunol. 1993. PMID: 7682587
-
Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii.Parasite Immunol. 2005 Jan-Feb;27(1-2):29-35. doi: 10.1111/j.1365-3024.2005.00738.x. Parasite Immunol. 2005. PMID: 15813720
-
Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents.J Infect Dis. 2000 Jan;181(1):317-24. doi: 10.1086/315186. J Infect Dis. 2000. PMID: 10608781
-
[Antigens of Toxoplasma gondii with a diagnostic and potential immunoprophylactic value: new strategies of identification].Ann Biol Clin (Paris). 1989;47(7):451-7. Ann Biol Clin (Paris). 1989. PMID: 2479305 Review. French.
-
[Problems and limitations of conventional and innovative methods for the diagnosis of Toxoplasmosis in humans and animals].Parassitologia. 2004 Jun;46(1-2):177-81. Parassitologia. 2004. PMID: 15305712 Review. Italian.
Cited by
-
Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review.J Adv Vet Anim Res. 2019 Mar 24;6(2):174-182. doi: 10.5455/javar.2019.f329. eCollection 2019 Jun. J Adv Vet Anim Res. 2019. PMID: 31453188 Free PMC article. Review.
-
Discovery of compounds blocking the proliferation of Toxoplasma gondii and Plasmodium falciparum in a chemical space based on piperidinyl-benzimidazolone analogs.Antimicrob Agents Chemother. 2014 May;58(5):2586-97. doi: 10.1128/AAC.01445-13. Epub 2014 Feb 18. Antimicrob Agents Chemother. 2014. PMID: 24550329 Free PMC article.
-
Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii.Parasit Vectors. 2014 Apr 13;7:180. doi: 10.1186/1756-3305-7-180. Parasit Vectors. 2014. PMID: 24726014 Free PMC article. Review.
-
Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model.Infect Immun. 2000 Sep;68(9):4948-53. doi: 10.1128/IAI.68.9.4948-4953.2000. Infect Immun. 2000. PMID: 10948109 Free PMC article.
-
Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice.Infect Immun. 1998 Sep;66(9):4503-6. doi: 10.1128/IAI.66.9.4503-4506.1998. Infect Immun. 1998. PMID: 9712808 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous